{"id":"https://openalex.org/W2337979309","doi":"https://doi.org/10.1093/ofid/ofv133.744","title":"Adverse Events (AE) and Laboratory Changes in a Real-World Population of Hepatitis C Virus (HCV)-Infected Patients With Chronic Kidney Disease (CKD) Treated With Sofosbuvir (SOF)-Based Therapy","display_name":"Adverse Events (AE) and Laboratory Changes in a Real-World Population of Hepatitis C Virus (HCV)-Infected Patients With Chronic Kidney Disease (CKD) Treated With Sofosbuvir (SOF)-Based Therapy","publication_year":2015,"publication_date":"2015-01-01","ids":{"openalex":"https://openalex.org/W2337979309","doi":"https://doi.org/10.1093/ofid/ofv133.744","mag":"2337979309"},"language":"en","primary_location":{"id":"doi:10.1093/ofid/ofv133.744","doi":"https://doi.org/10.1093/ofid/ofv133.744","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofv133.744","pdf_url":null,"source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1093/ofid/ofv133.744","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067275507","display_name":"Elke S. Backman","orcid":"https://orcid.org/0000-0003-2018-5527","observed_orcids":["https://orcid.org/0000-0003-2018-5527"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elke Backman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063217682","display_name":"Guillermo A. Ortiz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Guillermo Ortiz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063670543","display_name":"Gregory L. Hundemer","orcid":"https://orcid.org/0000-0003-3559-3531","observed_orcids":["https://orcid.org/0000-0003-3559-3531"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gregory Hundemer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008258452","display_name":"Nneka N. Ufere","orcid":"https://orcid.org/0000-0001-8255-9374","observed_orcids":["https://orcid.org/0000-0001-8255-9374"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nneka Ufere","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035211037","display_name":"Raymond T. Chung","orcid":"https://orcid.org/0000-0003-1338-9564","observed_orcids":["https://orcid.org/0000-0003-1338-9564"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Raymond Chung","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5048669465","display_name":"Meghan E. Sise","orcid":"https://orcid.org/0000-0002-4327-9713","observed_orcids":["https://orcid.org/0000-0002-4327-9713"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Meghan Sise","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4053,"currency":"USD","value_usd":4053},"apc_paid":{"value":4053,"currency":"USD","value_usd":4053},"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.16826604,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"2","issue":"suppl_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hepatitis-c","display_name":"hepatitis C","score":0.8109999895095825},{"id":"https://openalex.org/keywords/chronic-kidney-disease","display_name":"chronic kidney disease","score":0.996999979019165},{"id":"https://openalex.org/keywords/sofosbuvir","display_name":"sofosbuvir","score":0.9620000123977661},{"id":"https://openalex.org/keywords/direct-acting-antivirals","display_name":"direct-acting antivirals","score":0.9089999794960022},{"id":"https://openalex.org/keywords/ribavirin","display_name":"ribavirin","score":0.9409999847412109},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.9340000152587891},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6159999966621399},{"id":"https://openalex.org/keywords/renal-dysfunction","display_name":"renal dysfunction","score":0.6600000262260437},{"id":"https://openalex.org/keywords/hemoglobin-decline","display_name":"hemoglobin decrease","score":0.7110000252723694},{"id":"https://openalex.org/keywords/bilirubin","display_name":"bilirubin","score":0.7639999985694885},{"id":"https://openalex.org/keywords/simeprevir","display_name":"simeprevir","score":0.8429999947547913},{"id":"https://openalex.org/keywords/sustained-virologic-response","display_name":"sustained virological response","score":0.8730000257492065},{"id":"https://openalex.org/keywords/transplant-recipients","display_name":"transplant recipients","score":0.6069999933242798},{"id":"https://openalex.org/keywords/hiv-coinfection","display_name":"HIV coinfection","score":0.8040000200271606},{"id":"https://openalex.org/keywords/real-world-data","display_name":"real-world data","score":0.49300000071525574},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.5109999775886536},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.5049999952316284}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9289003014564514},{"id":"https://openalex.org/C2778390639","wikidata":"https://www.wikidata.org/wiki/Q2502747","display_name":"Sofosbuvir","level":5,"score":0.8260769844055176},{"id":"https://openalex.org/C2776408679","wikidata":"https://www.wikidata.org/wiki/Q708693","display_name":"Hepatitis C virus","level":3,"score":0.6738595962524414},{"id":"https://openalex.org/C2778653478","wikidata":"https://www.wikidata.org/wiki/Q1054718","display_name":"Kidney disease","level":2,"score":0.6060165166854858},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5956053137779236},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.5700684189796448},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.4929490089416504},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4643248915672302},{"id":"https://openalex.org/C2776455275","wikidata":"https://www.wikidata.org/wiki/Q154869","display_name":"Hepatitis C","level":2,"score":0.4642679691314697},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.45968127250671387},{"id":"https://openalex.org/C2776485726","wikidata":"https://www.wikidata.org/wiki/Q17141389","display_name":"Rescue therapy","level":2,"score":0.4437967538833618},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.44310545921325684},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.32229703664779663},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3208150863647461},{"id":"https://openalex.org/C2780040827","wikidata":"https://www.wikidata.org/wiki/Q421862","display_name":"Ribavirin","level":4,"score":0.23863822221755981},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1093/ofid/ofv133.744","doi":"https://doi.org/10.1093/ofid/ofv133.744","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofv133.744","pdf_url":null,"source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1093/ofid/ofv133.744","doi":"https://doi.org/10.1093/ofid/ofv133.744","is_oa":true,"landing_page_url":"https://doi.org/10.1093/ofid/ofv133.744","pdf_url":null,"source":{"id":"https://openalex.org/S2735126445","display_name":"Open Forum Infectious Diseases","issn_l":"2328-8957","issn":["2328-8957"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","norway-1","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Open Forum Infectious Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":5,"referenced_works":["https://openalex.org/W1966761464","https://openalex.org/W2113615736","https://openalex.org/W2136228822","https://openalex.org/W2149000288","https://openalex.org/W2417924786"],"related_works":["https://openalex.org/W2750695533","https://openalex.org/W3173188794","https://openalex.org/W7217450935","https://openalex.org/W2989579350","https://openalex.org/W3156970679","https://openalex.org/W2936893637","https://openalex.org/W3010159134","https://openalex.org/W7116933013","https://openalex.org/W2748231638","https://openalex.org/W2995515444"],"abstract_inverted_index":{"Background.":[0],"There":[1],"is":[2,22,44],"limited":[3],"safety":[4,74],"data":[5],"available":[6],"for":[7,24,60,73],"patients":[8,25,53,190,196,219],"with":[9,12,26,54,194,291],"CKD":[10,55,77,295],"treated":[11],"direct-acting":[13],"antiviral":[14],"therapy.":[15],"Although":[16],"no":[17],"dosage":[18],"adjustment":[19],"of":[20,83,144,287],"SOF":[21,38,149],"required":[23],"mild":[27],"to":[28,35,98,199,223,234,240,258,300],"moderate":[29],"renal":[30],"impairment":[31],"(CrCl":[32],"30":[33],"mL/min":[34,178,182],"80":[36],"mL/min),":[37],"area":[39],"under":[40],"the":[41,81],"curve":[42],"(AUC)":[43],"increased":[45,249],"in":[46,141,161,211,218,278,294],"these":[47],"individuals.":[48],"Methods.":[49],"Data":[50],"from":[51,172,256],"72":[52],"who":[56],"began":[57],"SOF-based":[58,292],"therapy":[59,293],"chronic":[61],"HCV":[62],"infection":[63],"between":[64],"November":[65],"2013":[66],"and":[67,75,117,130,150,303],"December":[68],"2014":[69],"were":[70,96,111,114,119,139,266],"evaluated":[71],"retrospectively":[72],"tolerability.":[76],"was":[78,105,159,208,216,306],"defined":[79],"by":[80,250],"presence":[82],"albuminuria":[84],">30":[85],"mg/g":[86],"or":[87],"glomerular":[88],"filtration":[89],"rate":[90,206],"<60":[91],"mL/min.":[92],"Ribavirin":[93],"(RBV)-containing":[94],"regimens":[95,138],"compared":[97,222],"those":[99,224],"without":[100],"RBV.":[101],"Results.":[102],"Median":[103],"age":[104],"61":[106],"\u00b1":[107],"8":[108,214],"years,":[109],"60%":[110],"white,":[112],"45%":[113],"transplant":[115],"recipients,":[116],"7%":[118],"HIV":[120],"coinfected.":[121],"At":[122],"baseline,":[123],"41":[124],"(57%)":[125],"had":[126,133],"stage":[127,134],"3":[128],"CKD,":[129],"31":[131],"(43%)":[132],"1-2":[135],"CKD.":[136],"RBV-containing":[137],"used":[140],"26":[142],"(36%)":[143],"patients,":[145,163,296],"36":[146],"(50%)":[147],"received":[148],"simeprevir.":[151],"Transient":[152],"creatinine":[153],"rise":[154],"\u22650.3":[155],"mg/dL":[156,252,270],"during":[157],"treatment":[158,301],"noted":[160],"63":[162],"but":[164,261,297],"on-treatment":[165],"average":[166,268],"eGFR":[167],"did":[168],"not":[169,307],"differ":[170],"significantly":[171],"baseline":[173,257,272],"[mean":[174],"(95%":[175],"CI):":[176],"57":[177],"(52-62)":[179],"versus":[180,236],"58":[181],"(53-63),":[183],"respectively,":[184],"P":[185],"=":[186,244,254,274],"0.26].":[187],"55":[188],"(76%)":[189],"experienced":[191],"an":[192],"AE":[193],"5":[195],"discontinuing":[197],"due":[198],"AEs":[200],"(table).":[201],"The":[202],"sustained":[203],"viral":[204],"response":[205],"(SVR12)":[207],"75%.":[209],"Change":[210],"hemoglobin":[212],"at":[213],"weeks":[215],"greater":[217],"receiving":[220],"RBV":[221],"on":[225,267],"a":[226],"RBV-free":[227],"regimen":[228],"[median":[229],"(Q1-Q3):":[230],"\u22121.8":[231],"g/dL":[232,238],"\u22123.6":[233],"\u22121.0)":[235],"\u22120.4":[237],"(\u22121.4":[239],"0.1),":[241],"respectively;":[242],"p":[243],"0.005].":[245],"Mean":[246],"total":[247],"bilirubin":[248],"0.52":[251],"(p":[253,273],"0.01)":[255],"week":[259,263],"4":[260,264],"post-treatment":[262],"levels":[265],"0.19":[269],"below":[271],"0.015).":[275],"*Prompted":[276],"discontinuation":[277,302],"\u22651":[279],"Conclusion.":[280],"We":[281],"identified":[282],"higher":[283],"than":[284],"expected":[285],"rates":[286],"side":[288],"effects":[289],"associated":[290],"few":[298],"led":[299],"significant":[304],"nephrotoxicity":[305],"noted.":[308],"Disclosures.":[309],"R.":[310],"Chung,":[311],"Gilead:":[312,318],"Investigator,":[313,319],"Research":[314,320],"grant;":[315],"M.":[316],"Sise,":[317],"grant":[321]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2016-06-24T00:00:00"}